These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 35596935

  • 1. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
    Cooper TJ, Cleland JGF, Guazzi M, Pellicori P, Ben Gal T, Amir O, Al-Mohammad A, Clark AL, McConnachie A, Steine K, Dickstein K.
    Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
    [Abstract] [Full Text] [Related]

  • 2. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial.
    JAMA; 2013 Mar 27; 309(12):1268-77. PubMed ID: 23478662
    [Abstract] [Full Text] [Related]

  • 3. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA.
    Eur Heart J; 2015 Oct 07; 36(38):2565-73. PubMed ID: 26188003
    [Abstract] [Full Text] [Related]

  • 4. Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease. Letter regarding the article 'Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial'.
    Dandel M, Hetzer R.
    Eur J Heart Fail; 2022 Oct 07; 24(10):1990. PubMed ID: 35853842
    [No Abstract] [Full Text] [Related]

  • 5. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Liu LC, Hummel YM, van der Meer P, Berger RM, Damman K, van Veldhuisen DJ, Voors AA, Hoendermis ES.
    Eur J Heart Fail; 2017 Jan 07; 19(1):116-125. PubMed ID: 27873388
    [Abstract] [Full Text] [Related]

  • 6. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F.
    BMC Cardiovasc Disord; 2020 Sep 10; 20(1):408. PubMed ID: 32912157
    [Abstract] [Full Text] [Related]

  • 7. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I, Mohammed SF, Forfia PR, Lewis GD, Borlaug BA, Gallup DS, Redfield MM.
    Circ Heart Fail; 2016 Apr 10; 9(4):e002729. PubMed ID: 27072860
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
    Jiang R, Wang L, Zhu CT, Yuan P, Pudasaini B, Zhao QH, Gong SG, He J, Liu JM, Hu QH.
    Hypertens Res; 2015 Dec 10; 38(12):829-39. PubMed ID: 26202179
    [Abstract] [Full Text] [Related]

  • 9. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Kim KH, Kim HK, Hwang IC, Cho HJ, Je N, Kwon OM, Choi SJ, Lee SP, Kim YJ, Sohn DW.
    Am Heart J; 2015 Jun 10; 169(6):813-822.e3. PubMed ID: 26027619
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R, Dhakal BP, Eisman AS, Pappagianopoulos PP, Dress A, Weiner RB, Baggish AL, Semigran MJ, Lewis GD.
    Circ Heart Fail; 2016 Jun 10; 9(6):. PubMed ID: 27301469
    [Abstract] [Full Text] [Related]

  • 11. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M, Vicenzi M, Arena R, Guazzi MD.
    Circulation; 2011 Jul 12; 124(2):164-74. PubMed ID: 21709061
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
    De Vecchis R, Cesaro A, Ariano C.
    Minerva Cardioangiol; 2018 Oct 12; 66(5):659-670. PubMed ID: 28398017
    [Abstract] [Full Text] [Related]

  • 13. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.
    Circulation; 2007 Oct 02; 116(14):1555-62. PubMed ID: 17785618
    [Abstract] [Full Text] [Related]

  • 14. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Böhm M, Teerlink JR, Docherty KF, Lopes RD, Divanji PH, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Felker GM.
    JAMA; 2022 Jul 19; 328(3):259-269. PubMed ID: 35852527
    [Abstract] [Full Text] [Related]

  • 15. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
    Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, Dickstein K.
    Eur J Heart Fail; 2013 Jan 19; 15(1):119-22. PubMed ID: 23097067
    [Abstract] [Full Text] [Related]

  • 16. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA, Lewis GD, McNulty SE, Semigran MJ, LeWinter M, Chen H, Lin G, Deswal A, Margulies KB, Redfield MM.
    Circ Heart Fail; 2015 May 19; 8(3):533-41. PubMed ID: 25782985
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM.
    J Am Coll Cardiol; 2014 Aug 12; 64(6):541-9. PubMed ID: 25104521
    [Abstract] [Full Text] [Related]

  • 18. The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial.
    Fernandes AM, Andrade AC, Barroso ND, Borges IC, Carvalho-Andrade D, Rodrigues Junior ES, Guimarães LC, Durães AR, Borges SM, Aras Junior R.
    PLoS One; 2015 Aug 12; 10(3):e0119623. PubMed ID: 25793988
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.